New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Content Format:

Slideset

Credit Type:

--

Credits:

--
New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.50
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Antibody–Drug Conjugates in EGFR-Mutated NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.25
Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2

Content Format:

Video

Credit Type:

AMA

Credits:

1.50
A Year in Review: ADCs Targeting HER3 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Current Considerations for Adverse Event Management With HER3-Directed Agents

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
2023 World Conference on Lung Cancer: Expert Perspectives on Key Studies

Content Format:

Text Module

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.50
Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Content Format:

Slideset

Credit Type:

--

Credits:

--
HER3-Targeted Antibody–Drug Conjugates for Lung and Breast Cancers: Where We Are Today

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
2023 World Conference on Lung Cancer Preview: Experts Choose the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Content Format:

Video

Credit Type:

AMA

Credits:

1.00
FAQs: Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Current Investigational Treatments Targeting HER3 in EGFR-Positive Post-TKI NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

1.25
Expert Think Tank: Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Antibody–Drug Conjugates in Lung Cancer Care

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Antibody–Drug Conjugates in Lung Cancer Care

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Mechanisms of Resistance to EGFR TKI Therapy in Advanced Lung Cancer

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Mechanisms of Resistance to EGFR TKI Therapy in Advanced Lung Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Treatment for EGFR-Mutant Lung Cancer After Progression on EGFR TKI

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Treatment for EGFR-Mutant Lung Cancer After Progression on EGFR TKI

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Role of HER3 in Lung Cancer

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Role of HER3 in Lung Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.00
My Thoughts on When to Consider ADCs for Today’s Patients With Advanced NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Express PointsCongress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Activity of ADCs in Clinical Trials for Lung Cancer: Anti-HER2/HER3 ADCs

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Data From ESMO 2020 Informing Precision Medicine in NSCLC: Podcast Pearls

Content Format:

PDF

Credit Type:

--

Credits:

--
Shared Decision-Making and the Current Landscape of Checkpoint Inhibitor Therapy in Metastatic NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--